Immunotherapy shows promise against Hard-to-Treat colorectal cancer
Disease control
Completed
This phase 2 study tested the immunotherapy drug prolgolimab in 30 people with a specific type of colorectal cancer (MSI/dMMR) that had not spread. Participants received the drug for 6 months before planned surgery. The main goal was to see if the cancer completely disappeared in…
Phase: PHASE2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC